Mycophenolate Mofetil (MMF) in Patients With IgA Nephropathy

Stopped early · Phase 3 · Has a placebo group

Conditions studied: IgA Nephropathy

In brief

IgA nephropathy (IgAN) is the most common type of glomerulonephritis worldwide. 15-40% of individuals diagnosed with IgAN, including children, will eventually progress to chronic renal insufficiency (CRI) and end stage renal disease (ESRD). The study is to evaluate the safety and benefits of MMF in patients with IgAN who have been pre-treated (and continue to be treated) with angiotensin converting enzyme inhibitors (ACEi) and fish oil supplements (FOS).

Key facts

Study ID

NCT00318474

Run by

St. Joseph's Hospital and Medical Center, Phoenix

People needed

184

Starts

2002-01-01

Expected to finish

2010-03-01

Last updated by the study team

2016-03-07

Who can join

Age: 7 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients ages 7-70 years old
• Renal biopsy, diagnostic for IgA nephropathy
• Must be able to take oral medication

You may not qualify if…

• Clinical and histologic evidence of systemic lupus erythematosus
• Well-documented history of Henoch-Schonlein purpura.
• Clinical evidence of cirrhosis or chronic liver disease
• Abnormal laboratory values at the time of study entry
• Estimated GFR outside of protocol defined limits
• History of significant gastrointestinal disorder
• Active systemic infection or history of serious infection within one month of entry or known infection with HIV, hepatitis B, or hepatitis C.
• Other major organ system disease or malignancy
• Current or prior treatment with MMF or azathioprine

Where it is running

• St. Joseph's Hospital and Medical Center — Phoenix, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.